Developer docs
API playgroundTry for free, no card

Search company profiles

Optibrium

Full company profile

uuid0002dcu

Namestring
Optibrium
Legal namestring
Optibrium Ltd.
Websiteurl
optibrium.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Optibrium Ltd. is a privately held Cambridge, UK-based software company that develops AI-powered computational platforms for small molecule drug discovery, founded in 2009 by Matthew Segall through a management buyout of the StarDrop business from BioFocus DPI. The company's product portfolio is centred on StarDrop, a modular platform for molecular design, optimisation, SAR analysis and multi-parameter scoring, and extends through three complementary offerings: Cerella (an AI-guided discovery platform built on deep learning imputation, branded Augmented Chemistry), Semeta (metabolite prediction software combining quantum mechanics and machine learning for DMPK scientists), and BioPharmics (3D ligand-based and structure-based design, including macrocycle modelling, acquired in 2023). Underlying capabilities span generative chemistry (Nova module), ADME/QSAR predictive modelling, multi-parameter optimisation, and physics-informed machine learning for binding affinity (QuanSA), with integrations to more than 15 third-party chemistry data and tooling platforms. The technology is protected by granted US patents (9,224,098 and 9,367,812), an extensive trademark portfolio, and ISO 27001 certification, and is backed by a science team including globally recognised cheminformatics authorities.

Optibrium serves pharmaceutical and biotech drug discovery organisations globally, with a stated base of 200+ teams across 170+ customer organisations including five of the world's top ten pharma and biotech companies. The go-to-market combines direct enterprise sales in the UK and US, regional distributor partnerships for Japan (Hulinks Inc.) and China (Shanghai CloudScientific), and an event- and content-led demand generation model. Customers span large-cap pharma (Sanofi, Johnson & Johnson, UCB, Grünenthal, Bial, Evotec) and emerging biotechs (Cerevance, adMare BioInnovations, Apollo Therapeutics, Anima Biotech).

Revenue is generated primarily through annual subscription licences for the StarDrop platform and its modules, with pricing starting near $10,000 and scaling to six figures for global site licences spanning multiple modules; professional services and training are bundled into subscriptions. Recurring revenue is supplemented by optional AWS-hosted cloud delivery at a small additional charge. The company has been funded by an Innovate UK grant (2018), equity investment from Kester Capital (2021 and 2022), and a multi-million-pound debt facility from Shawbrook Bank (July 2025) earmarked for generative chemistry, molecular modelling improvements, and global expansion.

Short descriptiontext

Optibrium develops AI-powered computational drug discovery software for small molecule design and optimisation, serving pharmaceutical and biotech companies globally through its StarDrop platform and complementary Cerella, Semeta, and BioPharmics products across 170+ organisations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computer-aided drug discovery, molecular design software, cheminformatics platform, ADMET prediction software, multi-parameter optimization
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Software Publishers5132
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Software
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software Licenses and Subscriptions
TypeSubscription Recurring
Description

Annual subscription-based licensing model for StarDrop and related software products. Modular pricing allows customers to customize packages with core features and specialized modules. Options include single-user, site-wide, company-wide, and floating licenses. Pricing starts at approximately $10,000 annually and scales to six figures for large global site licenses with multiple modules.

optibrium.com
2Professional Services and Training
TypeProfessional Services
Description

Onboarding, training, and implementation services. The company offers tailored hands-on training delivered on-site or virtually as part of the subscription package, with additional custom integrations available.

optibrium.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details4 tiers
1Core StarDrop Platform - Starting Tier
ModelSubscriptionBilling cadenceAnnual
Notes

Core platform with data visualisation, molecular design, multi-parameter optimisation (MPO), and SAR analysis capabilities. Annual subscription starting at approximately $10,000 per year for the base platform.

optibrium.com
2Extended Modules Tier
ModelSubscriptionBilling cadenceAnnual
Notes

Add-on specialized modules extending core capabilities: ADME QSAR, generative chemistry (Nova), 3D ligand/structure-based design (eSim3D/Surflex-Dock), metabolism prediction, advanced MPO (MPO Explorer), database access, and collaborative design (Idea Tracker). Scales with the number of modules selected.

optibrium.com
3Enterprise/Global Site License
ModelSubscriptionBilling cadenceAnnual
Notes

Full company-wide or multi-site deployment with multiple modules, potentially reaching six-figure annual costs. Includes floating licenses allowing multiple team members to share access cost-effectively.

optibrium.com
4Cloud Hosting Add-on
ModelSubscriptionBilling cadenceAnnual
Notes

Optional managed cloud hosting via AWS at a small additional charge, with the company noting total cost of ownership tends to be lower for users compared to on-premises deployment.

optibrium.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1StarDrop
Description

A complete platform for molecular design, optimisation and data analysis with an accessible and intuitive interface for computer-aided drug discovery.

optibrium.com
+3 more records
Core offering1 text field

Optibrium develops and licenses modular drug-discovery software for small-molecule design, optimisation, and data analysis. Its core offerings — StarDrop (a complete molecular design platform), Cerella (AI-guided discovery using deep learning imputation), Semeta (metabolite prediction for DMPK scientists) and BioPharmics (3D ligand/structure-based design) — are sold as annual subscriptions to pharmaceutical and biotech companies, supplemented by training, support, and cloud-hosting services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 25% reduction in hit-to-candidate costs compared to alternatives like LiveDesign
+5 more records
Product overview1 text field

Optibrium offers a modular platform-plus-products architecture for small molecule drug discovery. The core platform is StarDrop, a comprehensive molecular design, optimization, and data analysis platform available as a modular subscription with specialized add-on modules including ADME QSAR for property prediction, Nova for generative chemistry, eSim3D for 3D structure-based design, Metabolism Module for Phase I/II prediction, Auto-Modeller for custom QSAR model building, MPO Explorer for multi-parameter optimization, and Inspyra for synthesis planning. Complementary products include Cerella for AI-guided discovery using deep learning imputation, Semeta for standalone metabolite prediction tailored to DMPK scientists, and BioPharmics for 3D ligand and structure-based design (acquired in 2023). Key capabilities span predictive ADME modeling, generative chemistry, QSAR analysis, multi-parameter optimization, and 3D molecular visualization, serving over 200 chemistry teams globally including top pharmaceutical companies.

Product and service4 records
1StarDrop
CategoryDrug Discovery Platform (Core)
Description

Modular, subscription-licensed platform for small-molecule design, optimisation and data analysis, supporting SAR analysis, ADMET prediction, multi-parameter optimisation, 3D ligand/structure-based design, generative chemistry, and real-time team collaboration. Targeted at medicinal chemists, computational chemists, DMPK scientists and heads of drug discovery in pharmaceutical and biotech organisations.

2Cerella
CategoryAI-Guided Drug Discovery Platform
Description

AI-guided drug discovery platform that uses deep-learning imputation (Augmented Chemistry) to extract value from limited and noisy discovery data, predict compound properties and identify the most valuable experiments. Targeted at medicinal chemists and discovery project teams that need accurate predictions despite sparse datasets.

3Semeta
CategoryDMPK / Metabolism Prediction Software
Description

Stand-alone metabolite prediction software tailored for DMPK scientists, predicting Phase I and II metabolic routes, sites, products and lability across CYPs, FMOs, AOXs, UGTs and SULTs enzyme families using quantum-mechanics and machine-learning models. Supports species selection for preclinical studies and reactive-metabolite risk assessment.

4BioPharmics
Category3D Molecular Modelling Software
Description

3D ligand-based and structure-based molecular modelling platform for small molecules through to large macrocycles, covering virtual screening, similarity search, molecular docking (Surflex-Dock), binding-affinity prediction (QuanSA, FEP-equivalent accuracy) and conformational ensemble fitting (xGen). Targeted at medicinal chemists and computational chemists requiring 3D structure-based design capability.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Hulinks Inc.
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for StarDrop software in Japan, serving pharmaceutical and biotech companies in the Japanese market. Located in Tokyo.

optibrium.com
2Shanghai CloudScientific Information Technology Co. Ltd.
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for StarDrop software in China, serving pharmaceutical and biotech companies in the Chinese market. Located in Shanghai.

optibrium.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

EU-funded PhD programme partnership focused on developing faster and more accurate methods for predicting drug metabolism. Part of Optibrium's commitment to advancing sustainable drug discovery research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cloud-based life sciences R&D platform covering molecule registration, assay data, and registry workflows. Competes for the same medicinal chemistry and discovery informatics buyer, though with broader lab informatics scope.

TypeBroad incumbent
Description

Enterprise scientific software suite (Discovery Studio, Pipeline Pilot, BIOVIA Workbook) covering molecular modeling, registration, and lab informatics. Broader scope than Optibrium, but overlaps in computational chemistry for pharma R&D.

TypeDirect peer
Description

Public computational chemistry and molecular simulation platform serving pharma/biotech drug discovery. Closest direct competitor, particularly in physics-based modeling and predictive ADMET, with significantly larger scale and broader platform footprint.

TypeBroad incumbent
Description

Provider of biosimulation and drug development software (e.g., Phoenix, Synchrogenix). Larger incumbent in model-informed drug development with overlap in DMPK and ADMET prediction adjacent to Semeta.

TypeEmerging player
Description

CDD Vault database platform for collaborative drug discovery data management. Direct integration partner with StarDrop but partial overlap in cheminformatics, SAR analysis, and biological data handling.

TypeDirect peer
Description

Scientific R&D platform for chemistry, biology, and formulation workflows. Competes with StarDrop in cheminformatics, data visualization, and SAR analysis for pharma/biotech discovery teams.

TypeDirect peer
Description

Cheminformatics and molecular modeling software (Flare, Torch, Spark) used by medicinal chemists for 3D ligand-based design. Overlaps with StarDrop's 3D design, SAR analysis, and compound optimization workflows.

TypeDirect peer
Description

Developer of the Molecular Operating Environment (MOE) drug discovery platform. Long-standing direct competitor in computational chemistry, docking, QSAR, and medicinal chemistry workflows.

TypeDirect peer
Description

Provider of ADMET and PBPK modeling software (e.g., GastroPlus, ADMETPredictor). Directly comparable to Semeta for metabolism prediction and to ADME QSAR modeling within StarDrop.

TypeDirect peer
Description

Molecular modeling and cheminformatics software (e.g., Orion, Floe, OpenEye Suite). Directly competes in 3D ligand-based design, virtual screening, and ADMET prediction for small molecule discovery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration18 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Optibrium

Drug Discovery Softwareoptibrium.com

Optibrium develops AI-powered computational drug discovery software for small molecule design and optimisation, serving pharmaceutical and biotech companies globally through its StarDrop platform and complementary Cerella, Semeta, and BioPharmics products across 170+ organisations.

What Optibrium does

Optibrium Ltd. is a privately held Cambridge, UK-based software company that develops AI-powered computational platforms for small molecule drug discovery, founded in 2009 by Matthew Segall through a management buyout of the StarDrop business from BioFocus DPI. The company's product portfolio is centred on StarDrop, a modular platform for molecular design, optimisation, SAR analysis and multi-parameter scoring, and extends through three complementary offerings: Cerella (an AI-guided discovery platform built on deep learning imputation, branded Augmented Chemistry), Semeta (metabolite prediction software combining quantum mechanics and machine learning for DMPK scientists), and BioPharmics (3D ligand-based and structure-based design, including macrocycle modelling, acquired in 2023). Underlying capabilities span generative chemistry (Nova module), ADME/QSAR predictive modelling, multi-parameter optimisation, and physics-informed machine learning for binding affinity (QuanSA), with integrations to more than 15 third-party chemistry data and tooling platforms. The technology is protected by granted US patents (9,224,098 and 9,367,812), an extensive trademark portfolio, and ISO 27001 certification, and is backed by a science team including globally recognised cheminformatics authorities.

Optibrium serves pharmaceutical and biotech drug discovery organisations globally, with a stated base of 200+ teams across 170+ customer organisations including five of the world's top ten pharma and biotech companies. The go-to-market combines direct enterprise sales in the UK and US, regional distributor partnerships for Japan (Hulinks Inc.) and China (Shanghai CloudScientific), and an event- and content-led demand generation model. Customers span large-cap pharma (Sanofi, Johnson & Johnson, UCB, Grünenthal, Bial, Evotec) and emerging biotechs (Cerevance, adMare BioInnovations, Apollo Therapeutics, Anima Biotech).

Revenue is generated primarily through annual subscription licences for the StarDrop platform and its modules, with pricing starting near $10,000 and scaling to six figures for global site licences spanning multiple modules; professional services and training are bundled into subscriptions. Recurring revenue is supplemented by optional AWS-hosted cloud delivery at a small additional charge. The company has been funded by an Innovate UK grant (2018), equity investment from Kester Capital (2021 and 2022), and a multi-million-pound debt facility from Shawbrook Bank (July 2025) earmarked for generative chemistry, molecular modelling improvements, and global expansion.

Optibrium firmographics

Firmographics
Name
Optibrium
Legal name
Optibrium Ltd.
Website
https://optibrium.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Optibrium develops AI-powered computational drug discovery software for small molecule design and optimisation, serving pharmaceutical and biotech companies globally through its StarDrop platform and complementary Cerella, Semeta, and BioPharmics products across 170+ organisations.
Ownership category
akta.pro rank

Optibrium industry classification

Industry
Product category
Drug Discovery Software
NAICS
Software Publishers (5132), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Computer-aided drug discovery
  • Molecular design software
  • Cheminformatics platform
  • ADMET prediction software
  • Multi-parameter optimization

Where Optibrium is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Optibrium business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Software Licenses and Subscriptions: Annual subscription-based licensing model for StarDrop and related software products. Modular pricing allows customers to customize packages with core features and specialized modules. Options include single-user, site-wide, company-wide, and floating licenses. Pricing starts at approximately $10,000 annually and scales to six figures for large global site licenses with multiple modules.
  2. Professional Services and Training: Onboarding, training, and implementation services. The company offers tailored hands-on training delivered on-site or virtually as part of the subscription package, with additional custom integrations available.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCore StarDrop Platform - Starting Tier
SubscriptionAnnualExtended Modules Tier
SubscriptionAnnualEnterprise/Global Site License
SubscriptionAnnualCloud Hosting Add-on

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Optibrium product offering

Product offering

Core offering

Optibrium develops and licenses modular drug-discovery software for small-molecule design, optimisation, and data analysis. Its core offerings — StarDrop (a complete molecular design platform), Cerella (AI-guided discovery using deep learning imputation), Semeta (metabolite prediction for DMPK scientists) and BioPharmics (3D ligand/structure-based design) — are sold as annual subscriptions to pharmaceutical and biotech companies, supplemented by training, support, and cloud-hosting services.

Product overview

Optibrium offers a modular platform-plus-products architecture for small molecule drug discovery. The core platform is StarDrop, a comprehensive molecular design, optimization, and data analysis platform available as a modular subscription with specialized add-on modules including ADME QSAR for property prediction, Nova for generative chemistry, eSim3D for 3D structure-based design, Metabolism Module for Phase I/II prediction, Auto-Modeller for custom QSAR model building, MPO Explorer for multi-parameter optimization, and Inspyra for synthesis planning. Complementary products include Cerella for AI-guided discovery using deep learning imputation, Semeta for standalone metabolite prediction tailored to DMPK scientists, and BioPharmics for 3D ligand and structure-based design (acquired in 2023). Key capabilities span predictive ADME modeling, generative chemistry, QSAR analysis, multi-parameter optimization, and 3D molecular visualization, serving over 200 chemistry teams globally including top pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

  • StarDrop: A complete platform for molecular design, optimisation and data analysis with an accessible and intuitive interface for computer-aided drug discovery.
  • Cerella
  • BioPharmics
  • Semeta

Products and services

  • StarDrop Modular, subscription-licensed platform for small-molecule design, optimisation and data analysis, supporting SAR analysis, ADMET prediction, multi-parameter optimisation, 3D ligand/structure-based design, generative chemistry, and real-time team collaboration. Targeted at medicinal chemists, computational chemists, DMPK scientists and heads of drug discovery in pharmaceutical and biotech organisations.
  • Cerella AI-guided drug discovery platform that uses deep-learning imputation (Augmented Chemistry) to extract value from limited and noisy discovery data, predict compound properties and identify the most valuable experiments. Targeted at medicinal chemists and discovery project teams that need accurate predictions despite sparse datasets.
  • Semeta Stand-alone metabolite prediction software tailored for DMPK scientists, predicting Phase I and II metabolic routes, sites, products and lability across CYPs, FMOs, AOXs, UGTs and SULTs enzyme families using quantum-mechanics and machine-learning models. Supports species selection for preclinical studies and reactive-metabolite risk assessment.
  • BioPharmics 3D ligand-based and structure-based molecular modelling platform for small molecules through to large macrocycles, covering virtual screening, similarity search, molecular docking (Surflex-Dock), binding-affinity prediction (QuanSA, FEP-equivalent accuracy) and conformational ensemble fitting (xGen). Targeted at medicinal chemists and computational chemists requiring 3D structure-based design capability.

Quantifiable outcome

  • Up to 25% reduction in hit-to-candidate costs compared to alternatives like LiveDesign
  • +5 more outcomes

Companies that use Optibrium

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Optibrium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration18 records

AI capability8 records

Feature10 records

Optibrium partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered regional and minor.

  • Hulinks Inc.regionalChannel Partner/ Reseller/ DistributorRegional distributor for StarDrop software in Japan, serving pharmaceutical and biotech companies in the Japanese market. Located in Tokyo.
  • Shanghai CloudScientific Information Technology Co. Ltd.regionalChannel Partner/ Reseller/ DistributorRegional distributor for StarDrop software in China, serving pharmaceutical and biotech companies in the Chinese market. Located in Shanghai.
  • TalTech (Tallinn University of Technology)minorStrategic or Co-development PartnerEU-funded PhD programme partnership focused on developing faster and more accurate methods for predicting drug metabolism. Part of Optibrium's commitment to advancing sustainable drug discovery research.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Optibrium competitors and assessment

Company assessment

Direct peers

  • Benchling: Cloud-based life sciences R&D platform covering molecule registration, assay data, and registry workflows. Competes for the same medicinal chemistry and discovery informatics buyer, though with broader lab informatics scope.
  • Schrödinger: Public computational chemistry and molecular simulation platform serving pharma/biotech drug discovery. Closest direct competitor, particularly in physics-based modeling and predictive ADMET, with significantly larger scale and broader platform footprint.
  • Dotmatics: Scientific R&D platform for chemistry, biology, and formulation workflows. Competes with StarDrop in cheminformatics, data visualization, and SAR analysis for pharma/biotech discovery teams.
  • Cresset: Cheminformatics and molecular modeling software (Flare, Torch, Spark) used by medicinal chemists for 3D ligand-based design. Overlaps with StarDrop's 3D design, SAR analysis, and compound optimization workflows.
  • Chemical Computing Group (CCG): Developer of the Molecular Operating Environment (MOE) drug discovery platform. Long-standing direct competitor in computational chemistry, docking, QSAR, and medicinal chemistry workflows.
  • Simulations Plus: Provider of ADMET and PBPK modeling software (e.g., GastroPlus, ADMETPredictor). Directly comparable to Semeta for metabolism prediction and to ADME QSAR modeling within StarDrop.
  • OpenEye Scientific: Molecular modeling and cheminformatics software (e.g., Orion, Floe, OpenEye Suite). Directly competes in 3D ligand-based design, virtual screening, and ADMET prediction for small molecule discovery.

Broad incumbents

  • BIOVIA (Dassault Systèmes): Enterprise scientific software suite (Discovery Studio, Pipeline Pilot, BIOVIA Workbook) covering molecular modeling, registration, and lab informatics. Broader scope than Optibrium, but overlaps in computational chemistry for pharma R&D.
  • Certara: Provider of biosimulation and drug development software (e.g., Phoenix, Synchrogenix). Larger incumbent in model-informed drug development with overlap in DMPK and ADMET prediction adjacent to Semeta.

Emerging players

  • Collaborative Drug Discovery (CDD): CDD Vault database platform for collaborative drug discovery data management. Direct integration partner with StarDrop but partial overlap in cheminformatics, SAR analysis, and biological data handling.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Optibrium social profiles

Digital presence

Optibrium compliance and trust

Trust signal

Compliance1 record

Optibrium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Optibrium leadership team

Management profile

Number of profiles

Profiles13 records

Optibrium subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Optibrium funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Optibrium M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optibrium

What does Optibrium do?

Optibrium develops and licenses modular drug-discovery software for small-molecule design, optimisation, and data analysis. Its core offerings — StarDrop (a complete molecular design platform), Cerella (AI-guided discovery using deep learning imputation), Semeta (metabolite prediction for DMPK scientists) and BioPharmics (3D ligand/structure-based design) — are sold as annual subscriptions to pharmaceutical and biotech companies, supplemented by training, support, and cloud-hosting services.

Is Optibrium a public or private company?

Optibrium is a private company. It is classified as private equity controlled and is currently operating.

When was Optibrium founded?

Optibrium was founded in 2009. It employs 11 to 50 people.

Where is Optibrium based?

Optibrium is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Optibrium make money?

Two revenue lines are on record. Software Licenses and Subscriptions are the primary driver. The others are professional Services and Training.

Who are Optibrium's main competitors?

Direct peers on record are Benchling, Schrödinger, Dotmatics, Cresset, Chemical Computing Group (CCG), Simulations Plus and OpenEye Scientific. Broad incumbents are BIOVIA (Dassault Systèmes) and Certara. Collaborative Drug Discovery (CDD) is listed as an emerging player.

Does Optibrium have an API?

No public API is recorded for Optibrium.

What industry is Optibrium in?

Optibrium's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BiotechniquesThe biotech bi-weekly: cell barcoding, compound optimization and the Trillion Cell AtlasThis biotech industry roundup covers multiple product launches, partnerships, and organizational updates from the past two weeks, including Biotium's ViaPlex cell barcoding kit for multiplex analysis, Optibrium's QuanSA plugin for compound optimization, and Touchlight's EnClose cell-free DNA synthesis kit developed with New England Biolabs. Notable collaborations include iXCells' international partnership to evaluate chemotherapeutic toxicities in patient-specific organoids and Basecamp Research's launch of the Trillion Gene Atlas with Anthropic, Ultima Genomics, and PacBio to expand genomic data at scale. Additional updates include Ryvu Therapeutics presenting preclinical data at AACR 2026, Abselion appointing Dale Gordon as Chair, and ProImmune's collaboration with the University of Edinburgh's Roslin Institute on veterinary immunology research.News-MedicalOptibrium delivers real-time collaboration in its comprehensive molecular design platform with StarDrop 8Optibrium announced StarDrop 8, its most significant platform update in 20 years, integrating real-time collaboration into molecular design. The release includes new ADME property models and is available for evaluation upon request.News-MedicalAdvancing drug discovery with AI, generative chemistry, and 3D molecular designMatthew Segall, CEO of Optibrium, discussed the company's AI-powered software platforms for small molecule drug design and optimization in an interview. Optibrium has developed StarDrop, Cerella, and related technologies for multi-parameter optimization, generative chemistry, and 3D molecular modelling, having acquired BioPharmics in 2023 to expand its 3D ligand and structure-based design capabilities. The company is preparing to release StarDrop version 8 with enhanced collaboration features and upcoming research applying new machine learning methods to drug metabolism predictions.OptibriumOptibrium secures multi-million-pound financing package from Shawbrook to accelerate business growthOptibrium secured a multi-million-pound financing package from Shawbrook to accelerate product development and global expansion. The ARR-based deal will fund improvements in generative chemistry, collaborative design, and 3D molecular modelling. The global CADD market is projected to reach $13.08 billion by 2034.Discover-PharmaOptibrium secures multi-million-pound funding to power global AI drug discovery expansionOptibrium secured multi-million-pound funding from Shawbrook to support its AI drug discovery software. The company has over 160 global customers, and the CADD market is projected to grow from $4.21 billion in 2024 to $13.08 billion by 2034. The financing will advance core technologies and international expansion.Med-Tech InsightsOptibrium secures multi-million pound financing package to boost growth of AI-powered drug discoveryOptibrium secured a multi-million-pound financing package from Shawbrook to accelerate its AI-powered drug discovery software. The funding will support product development and global expansion, with over 160 organizations using its platforms. The global CADD market is projected to reach $13.08 billion by 2034.ZymecommunicationsOptibrium secures multi-million-pound financing package from Shawbrook to accelerate business growthOptibrium, a Cambridge-based developer of AI-driven computational chemistry software for drug discovery, has secured a multi-million-pound financing package from UK specialist bank Shawbrook to accelerate product development and global expansion. The ARR-based financing follows continued investment from Kester Capital since 2021 and will focus on enhancing generative chemistry, collaborative design, and 3D molecular modelling capabilities. The CADD market is projected to grow from $4.21 billion in 2024 to $13.08 billion by 2034 at a CAGR of 12%.Business WeeklyOptibrium raises multimillions to accelerate growthOptibrium raised multimillions from Shawbrook to accelerate product development and global expansion of its computational chemistry and AI-driven discovery technology. The financing will support generative chemistry, collaborative design, and 3D molecular modelling capabilities. The global CADD market is projected to reach $13.08 billion by 2034.News-MedicalOptibrium partners with TalTech on EU-funded PhD program to advance sustainable drug discoveryOptibrium and TalTech announced a partnership to co-supervise an EU-funded PhD position under the INNOCHEMBIO programme, focusing on developing accurate metabolism models. The research aims to replace computationally expensive physics-based methods with efficient machine learning interatomic potentials, integrating into Optibrium's StarDrop platform. The project is part of the Marie Sklodowska-Curie Actions COFUND programme, with 15 PhD positions funded.FmcThe Power of Partnership: Collaboration is vital to advancing crop protectionFMC described its strategy of advancing sustainable crop protection through partnerships, citing a multi-year research agreement with biotechnology firm AgroSpheres on RNAi technology and a collaboration with Optibrium on AI-driven small molecule discovery. The company reported over 20 new active areas in discovery and 18 new active ingredients in development. It also began a multi-year relationship with Purdue University's Department of Agricultural & Biological Engineering on plant sensor technology.